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(KidneyContents lists available at ScienceDirectEditorialVitamin C and functional iron deﬁciency anemia in hemodialysis$Functional iron deﬁciency (FID), referring to an impaired
provision of iron needed for erythropoiesis despite adequate
iron storage in the body (serum ferritin4100 mg/L and
transferrin saturation (TSAT)420%), is commonly observed
in dialysis patients, being found in about 20% of those
patients according to some European reports [1,2]. FID in
dialysis patients was vaguely known to be caused by chronic
inﬂammatory status and kidney dysfunction until the dis-
covery of hepcidin explained a large part of the pathophy-
siological mechanism [3].
Dialysis patients showed a signiﬁcantly skewed distribu-
tion and a wide variation of plasma vitamin C levels. In one
study, 15% of the hemodialysis (HD) patients had a severe
vitamin C deﬁciency (o10 mM). A higher plasma vitamin C
is associated with a lower plasma parathyroid hormone
(PTH) [4]. The effectiveness of vitamin C as an adjuvant
therapy for anemia in patients receiving erythrocyte-stimu-
lating agent (ESA) or intravenous iron has long been known.
It was already shown in 1995 that in dialysis patients
receiving transfusion, intravenous vitamin C improved the
anemia status which worsened again after discontinuation
of vitamin C [5]. Later studies have shown that vitamin C
treatment increased blood hemoglobin level, thereby redu-
cing the ESA dose requirement [6,7]. Hypochromic red blood
cells (HRC) reﬂect iron adequacy for erythropoiesis. A higher
HRC percentage is known to be associated with a better
response to vitamin C [8]. The direct mechanism, however,
behind the effect of vitamin C on anemia is not clear yet. One
hypothesis is that vitamin C affects mobilization of stored
iron from the Kupffer cells in the liver and other sites in the
reticuloendothelial system, increasing release of iron avail-
able for erythropoiesis [9].
Since its ﬁrst description in 2000, hepcidin, a peptide
hormone synthesized in the liver, has been shown to be
the central regulatory module for systemic iron home-
ostasis [10]. Hepcidin is in part removed from the body by
glomerular ﬁltration and degradation in the proximal
tubule [11]. With diminishing renal function, the renal
excretion and degradation of hepcidin is reduced while its132/$ - see front matter & 2012. The Korean Society of Nephrology.
.1016/j.krcp.2011.12.008
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Research and Clinical Practice J1_201100101).hepatic production is increased by the inﬂammatory
stimuli marked by elevated interleukin 6 (IL-6) [3]. As a
result, the blood hepcidin level is increased in dialysis
patients. Hepcidin in the human body controls absorption,
recycling, and tissue distribution of iron by decreasing
(1) iron absorption from the duodenum; (2) iron release
from the macrophages involved in recycling senescent red
blood cells; and (3) iron release from iron-storing hepa-
tocytes. The net result of elevated hepcidin is decreased
iron transfer into blood plasma, leading to FID [10] (Fig. 1).
The hepatic production of hepcidin is increased by inter-
leukin-6 (IL-6). Vitamin C counters inﬂammation as a
strong anti-oxidant and thus is believed to be involved
in hepcidin production, too. No study is available, how-
ever, to support a direct association between vitamin C
and hepcidin, except that alcohol represses the expression
of hepcidin messenger RNA, and that vitamin C increases
hepcidin expression in the liver of patients with alcoholic
liver disease [12]. Further research is needed to examine
the association between vitamin C treatment and hepcidin
in FID anemia of dialysis patients.
In dialysis patients, the two main axes of anemia treat-
ment are ESA and intravenous iron therapy, each with
respective problems. ESA is costly and associated with
increased risk of tumor growth, pure red cell aplasia,
cardiovascular complications including myocardial infarc-
tion and stroke, thrombosis and hypertension. Ultimately,
excess treatment with ESA might raise mortality [13–15].
On the other hand, intravenous iron therapy poses the risk
of anaphylaxis, oxidative stress, and infection [16].
In this issue of Kidney Research and Clinical Practice,
Kang et al [17] report that intravenous vitamin C is effective
on erythropoietin-resistant normoferritinemic anemia in
hemodialysis patients. Intravenous (IV) administration of
vitamin C (500 mg IV in each dialysis session for 3 months)
in the iron-replete normoferritinemic hemodialysis patients
(serum ferritin, 100–500 mg/L) was associated with an
increased hemoglobin level and a lower weekly erythropoie-
tin requirement in 61% of the patients. In the vitamin
C-responsive group of patients, serum iron levels and TSAT
scores went up whereas the serum ferritin decreased,
indicative of mobilization of stored iron. With such results
on the treatment efﬁcacy of vitamin C, one might suggestPublished by Elsevier. All rights reserved.
Figure 1. Functional iron deﬁciency status and increased hepcidin
level in chronic kidney disease.
IL-6, interleukin-6; RBC, red blood cells.
Kidney Res Clin Pract 31 (2012) 1–32that vitamin C lowers the risk of exposure to ESA or iron and
also the cost of treatment when used as an adjuvant therapy
for anemia. Attention, however, must be drawn to some of
the details of this particular study: (1) the sample size is a
little too small (control group, n¼25; treated group, n¼33)
and the accuracy of the study design is less than desirable,
which makes bias evaluation difﬁcult; (2) lack of data on the
amount of iron supplements used during the study; (3) lack
of data on intact PTH during the study period, since
hyperparathyroidism is one of the culprits for ESA resistance,
and there is a report that vitamin C is associated with
decreased PTH [4]; and (4) unclear description of the target
hemoglobin level and lack of evidence on which treatment
response was deﬁned. In addition, there was no measure-
ment provided of blood vitamin C or hepcidin levels.
In dialysis patients, dietary intake of vitamin C gets
easily insufﬁcient. Foods rich in vitamin C, such as fruit
juice and broccoli, also contain plenty of potassium, a
nutrient restricted for these patients. As a result, vitamin C
deﬁciency can readily occur [18], and matters get worse
given the heavy losses of vitamin C during hemodialysis
[19]. Use of vitamin C supplements also requires caution.
Vitamin C is metabolized into oxalic acid, and excess
oxalate accumulation leads to formation of oxalate crystal
deposits in the tissues [9]. Indeed, clinical trials using
vitamin C have generally been designed to be short term
(90–180 days) to avoid oxalosis [20]. It is necessary to
have a further large-scale, prospective, randomized clin-
ical trial on the long-term safety and efﬁcacy of vitamin C
as an adjuvant therapy for anemia.Acknowledgments
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